Omnicell, Inc. (NASDAQ:OMCL) Position Increased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 93.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,450,416 shares of the company’s stock after purchasing an additional 699,925 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Omnicell were worth $64,573,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of OMCL. GAMMA Investing LLC raised its stake in Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the period. Curi RMB Capital LLC grew its holdings in shares of Omnicell by 0.7% during the third quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock valued at $3,872,000 after purchasing an additional 651 shares during the last quarter. KBC Group NV raised its position in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after purchasing an additional 778 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Omnicell by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,459 shares of the company’s stock worth $635,000 after purchasing an additional 1,360 shares during the last quarter. Finally, 1620 Investment Advisors Inc. boosted its position in Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.64% of the company’s stock.

Omnicell Stock Up 1.9 %

Omnicell stock opened at $40.16 on Monday. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 148.75, a PEG ratio of 26.98 and a beta of 0.78. The company’s 50-day moving average price is $44.21 and its two-hundred day moving average price is $43.38. The company has a current ratio of 1.37, a quick ratio of 0.95 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, analysts expect that Omnicell, Inc. will post 1.04 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on OMCL. Wells Fargo & Company dropped their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Benchmark reaffirmed a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Craig Hallum upped their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, Bank of America cut their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Omnicell has an average rating of “Hold” and an average price target of $52.33.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.